What Digital Therapeutics Actually Are
Digital therapeutics (DTx) are distinct from general health and wellness apps. The Digital Therapeutics Alliance defines them as interventions that: deliver evidence-based therapeutic interventions to patients, are intended to treat or manage a medical disorder or disease, produce clinical outcomes that are measured and clinically validated, and meet regulatory requirements for effectiveness, safety, and data security.
Examples
Somryst: FDA-authorized digital therapeutic for chronic insomnia. Delivers cognitive behavioral therapy for insomnia (CBT-I) via smartphone app. Clinical trials showed non-inferiority to in-person CBT-I. Freespira: FDA-cleared device for panic disorder and PTSD. Teaches diaphragmatic breathing with real-time capnometry (CO2 measurement). 79% of patients showed clinically significant symptom reduction. reSET and reSET-O: FDA-authorized for substance use disorder. Delivers CBT-based modules with contingency management. Pear Therapeutics' prescription digital therapeutics suite.
The Regulatory Landscape
FDA Digital Health Innovation Action Plan establishes pathways for software-based medical devices. European CE marking for digital health products. Clinical trial requirements mirror pharmaceutical standards: randomized controlled trials, placebo or active comparators, sustained outcomes at follow-up. This regulatory rigor separates digital therapeutics from the unregulated wellness app market.
The Evidence Base
Meta-analyses show digital therapeutics can produce clinically meaningful improvements. A 2020 study in JMIR Mental Health found DTx for depression and anxiety showed moderate effect sizes (Cohen's d = 0.5-0.8), comparable to pharmacotherapy and face-to-face therapy. Advantages: scalability, consistency of delivery, real-time data collection, lower cost per patient.
What Makes Digital Therapeutics Work
Structured, evidence-based content (not generic advice), progressive skill-building (sequential modules with increasing complexity), personalization algorithms, engagement strategies (notifications, progress tracking, rewards), integration with clinical care (provider dashboards, clinical decision support), and rigorous outcome measurement.
The Gap
Current DTx primarily address clinical populations with diagnosed disorders. The subclinical space — people with significant distress who don't meet diagnostic thresholds — remains underserved. This is where most people actually live. Digital therapeutics principles (evidence-based, clinically validated, outcome-measured) could apply to this population, but few products exist.
Conclusion
Digital therapeutics demonstrate that technology, when designed with clinical rigor, can deliver genuine therapeutic benefit. The question is whether this model will expand beyond current clinical applications to serve the millions who need structured, evidence-based mental health support but won't access traditional clinical care.